Marvel Biosciences says MB-204 reverses cognitive, behavioral deficits in Fragile X mouse study

Reuters2026/08/05 09:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Marvel Biosciences reported positive preclinical results for MB-204 in a Fragile X (Fmr1 knockout) mouse study run via FRAXA-DVI.
Two-week oral dosing restored all tested behavioral and cognitive measures toward wild-type levels; high dose showed the strongest, most consistent effects.
Carry-over persisted two weeks post-treatment for high dose in locomotor activity, self-grooming, recognition memory; effects weakened versus on-treatment results.
Data extend MB-204 efficacy across three ASD-related preclinical models, supporting advancement toward clinical trials and broader orphan-indication positioning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050500PRIMZONEFULLFEED9803840) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Marvel Biosciences says MB-204 reverses cognitive, behavioral deficits in Fragile X mouse study

You may also like

Crypto prices